The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Michael C. Heinrich
Stock and Other Ownership Interests - MolecularMD
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; MolecularMD; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
Expert Testimony - Novartis
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Bayer; Blueprint Medicines; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Patrick Schoffski
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Deciphera
Consulting or Advisory Role - Adaptimmune (Inst); Advanced Medical (Inst); Blueprint Medicines; Blueprint Medicines (Inst); Boehringer Ingelheim; Deciphera; Ellipses Pharma; Ellipses Pharma (Inst); Exelixis; Guided Clarity; Intellisphere (Inst); Medscape; Transgene; Transgene (Inst); Ysios Capital
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Ipsen (Inst); MSD (Inst)
 
Cesar Serrano
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Immunicum
Speakers' Bureau - Blueprint Medicines
Research Funding - Karyopharm Therapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Karma Oncology; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Gina Z. D'Amato
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Epizyme
Speakers' Bureau - Janssen Oncology; Lilly
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; Exelixis; Merck (I)
Research Funding - Deciphera (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
 
Peter Reichardt
Honoraria - Amgen; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; BMS; Clinigen Group; Deciphera; MSD; Roche
Research Funding - Novartis (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune
 
Julie Nicole Meade
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
VIENNA Lynn REICHERT
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Kelvin Shi
Employment - Deciphera
Stock and Other Ownership Interests - Albireo Pharma; Alnylam; AstraZeneca; Deciphera; ImmunoGen; Karyopharm Therapeutics; Spectrum Pharmaceuticals
 
Matthew L. Sherman
Employment - Deciphera
Leadership - Pieris Pharmaceuticals
Stock and Other Ownership Interests - Deciphera
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
Other Relationship - Newlink Genetics
 
Rodrigo Ruiz-Soto
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Immunogen
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties
 
Margaret von Mehren
Consulting or Advisory Role - deciphera; Exelixis
Research Funding - Arog (Inst); ArQule; ASCO (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Lilly (Inst); Novartis (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera; NCCN
Other Relationship - NCCN
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche